Unveiling the potential of CLL-1: a promising target for AML therapy

Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation

MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis

Inhibitory effects of the β₂‐adrenergic receptor agonist zilpaterol on the LPS‐induced production of TNF‐α in vitro and in vivo